The biopharmaceutical pipeline is full of innovative new approaches that offer hope to patients.

### WHAT IS IN THE BIOPHARMACEUTICAL PIPELINE?

<table>
<thead>
<tr>
<th>Disease</th>
<th>Projects in Development</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CANCER</strong></td>
<td>4,000</td>
</tr>
<tr>
<td><strong>CARDIOVASCULAR DISEASE</strong></td>
<td>450</td>
</tr>
<tr>
<td><strong>ALZHEIMER'S DISEASE</strong></td>
<td>143</td>
</tr>
</tbody>
</table>

#### NEW SCIENTIFIC APPROACHES

- **CELL AND GENE THERAPIES**
- **DNA AND RNA THERAPEUTICS**
- **CONJUGATED MONOCLONAL ANTIBODIES**

74% of medicines in the clinical pipeline have the potential to be first-in-class, meaning they use a new approach to fight a disease.

95 percent of the 7,000 identified rare diseases have no approved medicines.

822 projects in development are designated as orphan drugs.

Medicines in the biopharmaceutical pipeline may bring hope to patients by providing:

- Greater efficacy
- Improved delivery
- Fewer side effects